Alvotech (NASDAQ: ALVO) inks Sandoz biosimilar pacts for Canada, Australia and New Zealand

Rhea-AI Filing Summary

Alvotech has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand. The collaboration is designed to create commercial pathways for Alvotech’s biosimilar portfolio in these markets ahead of regulatory approvals.

In Canada, the agreement covers one ophthalmology biosimilar candidate supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, it covers three biosimilar candidates in immunology and gastroenterology, in multiple formulations. Sandoz will handle regulatory submissions, commercialization and distribution, while Alvotech will manage development, global clinical activities and manufacturing and supply finished product under exclusive supply arrangements.

Insights

Biotech partnerships analyst

Alvotech expands regional reach through Sandoz-led commercialization of multiple biosimilars.

Alvotech is using agreements with Sandoz to secure commercialization routes for several biosimilar candidates in Canada, Australia and New Zealand. Sandoz will lead regulatory filings and sales, while Alvotech focuses on development, clinical work and manufacturing under exclusive supply deals.

This structure lets Alvotech leverage Sandoz’s established commercial infrastructure and regional expertise without building its own local sales platforms. The agreements span ophthalmology, immunology and gastroenterology, potentially broadening future revenue sources if the candidates gain approvals and successful launches.

Actual impact will depend on regulatory approvals and market uptake following launches in these territories, as described in the company’s forward-looking statements and risk-factor references.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number: 001-41421

Alvotech
(Translation of registrant's name into English)

9, Rue de Bitbourg,
L-1273 Luxembourg,
Grand Duchy of Luxembourg
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

Incorporation by Reference

This Report on Form 6-K (this “Report”) of Alvotech (the “Company”) excluding Exhibit 99.1 attached hereto, shall be deemed to be incorporated by reference into the Company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), the Company’s registration statement on Form F-3ASR (File No. 333-289006), and the Company’s registration statement on Form S-8 (File No. 333-266881) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibit 99.1 to this Report is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Press Releases

On February 2, 2026, Alvotech issued a Press Release announcing that the Company has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand. A copy of the Press Release is furnished herewith as exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated February 2, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Alvotech
		(Registrant)
Date: February 2, 2026		/s/ Tanya Zharov
		Tanya Zharov
		General Counsel

EXHIBIT 99.1

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has entered into supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, and in Australia and New Zealand.

“These agreements with Sandoz further advance Alvotech’s strategy of securing commercial pathways for its biosimilars portfolio across global markets ahead of regulatory approval,” said Róbert Wessman, Chairman. “These partnerships reflect the strength of our integrated development and manufacturing platform and our ability to work with experienced regional partners to expand patient access while maintaining capital discipline.”

In Canada, the agreement covers one biosimilar candidate in ophthalmology supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, the agreement encompasses three biosimilar candidates across immunology and gastroenterology, in multiple formulations. Sandoz will lead regulatory filings and commercial activities in the territories in close coordination with Alvotech. The collaboration is intended to support broad patient access following regulatory approvals and market launches across the region.

Under the agreements, Sandoz will be responsible for regulatory submissions, commercialization and distribution in the respective jurisdictions. Alvotech will retain responsibility for development, global clinical activities and manufacturing and will supply finished product to Sandoz under exclusive supply arrangements.

With a strong presence in Canada, Australia and New Zealand, Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and affordably.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad (US)
Patrik Ling (SE)
Benedikt Stefansson (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

Alvotech Forward-Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

FAQ

What did Alvotech (ALVO) announce in its new agreement with Sandoz?

Alvotech announced new supply and commercialization agreements with Sandoz covering multiple biosimilar candidates in Canada, Australia and New Zealand. Sandoz will lead regulatory and commercial activities, while Alvotech will handle development, clinical programs, manufacturing and exclusive finished-product supply.

Which markets are covered by Alvotech’s biosimilar agreements with Sandoz?

The agreements cover Canada, Australia and New Zealand. In Canada, they focus on one ophthalmology biosimilar candidate, while in Australia and New Zealand they include three biosimilar candidates across immunology and gastroenterology, with multiple formulations and Sandoz managing local commercialization.

How are responsibilities divided between Alvotech and Sandoz under these biosimilar deals?

Sandoz is responsible for regulatory submissions, commercialization and distribution in the covered territories. Alvotech retains responsibility for product development, global clinical activities and manufacturing, and will supply finished biosimilar products to Sandoz under exclusive supply arrangements.

What types of biosimilar candidates are included in Alvotech’s agreement for Canada?

In Canada, the agreement covers one ophthalmology biosimilar candidate. It is supplied as a prefilled syringe intended for intravitreal injection, with Sandoz managing regulatory and commercial efforts and Alvotech providing development, clinical work and manufacturing support.

What therapeutic areas are targeted by Alvotech’s Sandoz partnership in Australia and New Zealand?

In Australia and New Zealand, the agreement covers three biosimilar candidates across immunology and gastroenterology. These candidates will be provided in multiple formulations, with regulatory filings and commercialization led by Sandoz in close coordination with Alvotech.

How does this Sandoz collaboration fit Alvotech (ALVO)’s broader biosimilar strategy?

Alvotech states these agreements advance its strategy of securing commercial pathways for its biosimilar portfolio ahead of regulatory approval. By partnering with an experienced regional player, it aims to expand patient access while maintaining capital discipline in key international markets.